Review
doi: 10.1023/a:1011946030404.
DNA methylation as a target for drug design
Affiliations
- PMID: 9523301
- DOI: 10.1023/a:1011946030404
Item in Clipboard
Review
DNA methylation as a target for drug design
Pharm Res.
1998 Feb.
Abstract
DNA methylation is essential for normal embryonic development. Distinctive genomic methylation patterns must be formed and maintained with high fidelity to ensure the inactivities of specific promoters during development. The mutagenic and epigenetic aspects of DNA methylation are especially interesting because they may lead to the inactivation of genes which are involved in human carcinogenesis. The mutagenicity of 5-Methylcytosine (5mC) and the role of promoter hypermethylation in gene silencing, particularly in cancer, suggest a clinical significance for the design of novel DNA methylation inhibitors which may be utilized to reverse the effects of DNA methylation.
Similar articles
-
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78. doi: 10.1016/j.drup.2004.06.005. Drug Resist Updat. 2004. PMID: 15533764 Review.
-
Aberrant DNA methylation as a cancer-inducing mechanism.Annu Rev Pharmacol Toxicol. 2005;45:629-56. doi: 10.1146/annurev.pharmtox.45.120403.095832. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822191 Review.
-
DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis.Mutat Res. 1997 Apr 14;375(1):1-8. doi: 10.1016/s0027-5107(97)00003-1. Mutat Res. 1997. PMID: 9129674 Review.
-
Defining Driver DNA Methylation Changes in Human Cancer.Int J Mol Sci. 2018 Apr 12;19(4):1166. doi: 10.3390/ijms19041166. Int J Mol Sci. 2018. PMID: 29649096 Free PMC article. Review.
-
DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers.Tohoku J Exp Med. 2013 Mar;229(3):173-85. doi: 10.1620/tjem.229.173. Tohoku J Exp Med. 2013. PMID: 23419314 Review.
Cited by
-
Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.Cancer Drug Resist. 2021;4(1):125-142. doi: 10.20517/cdr.2020.95. Epub 2021 Mar 19. Cancer Drug Resist. 2021. PMID: 33796823 Free PMC article.
-
DNA and the chromosome - varied targets for chemotherapy.Cell Chromosome. 2004 May 24;3(1):2. doi: 10.1186/1475-9268-3-2. Cell Chromosome. 2004. PMID: 15157277 Free PMC article.
-
Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells.J Tissue Eng. 2014 Feb 18;5:2041731414524758. doi: 10.1177/2041731414524758. eCollection 2014. J Tissue Eng. 2014. PMID: 24555015 Free PMC article.
-
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells.Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14007-12. doi: 10.1073/pnas.96.24.14007. Proc Natl Acad Sci U S A. 1999. PMID: 10570189 Free PMC article.
-
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.N Engl J Med. 2022 May 26;386(21):1998-2010. doi: 10.1056/NEJMoa2119771. N Engl J Med. 2022. PMID: 35613022 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources